Application Note

Implementing FDA Guidance: CCI Testing In Lieu Of Sterility Testing

IMG_4392

The Food and Drug Administration released guidance in 2008 titled “Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products,” which provides recommendations for replacing sterility testing with alternative test methods as a means to confirm container and closure system integrity The purpose of this application note is to provide recommendations for replacing sterility as a means to confirm container and closure system integrity as a part of the stability protocol.

This application note will detail the requirements laid out in this guidance document, explain the method of operation of Lighthouse’s technology, detail how the method can be used to meet the FDA’s requirements, and detail a case study of a large multinational pharmaceutical company that implemented Lighthouse’s test method in lieu of sterility for their lyophilized drug products.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online